Novo Nordisk’s Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?
Novo Nordisk's GLP-1 pill is performing incredibly well, which is a good sign if you are considering buying the stock.
·
The Motley Fool
Defense Stocks Fell After the Midterms. Here’s the 1 Defense Name I’d Buy Anyway — and Why It Isn’t Lockheed Martin.
RTX is positioned to do well regardless of the political climate.
·
The Motley Fool
Is Tilray a Buy at Its Record Low, or Is It a Value Trap?
Tilray’s recent record revenue wasn’t as impressive as it seemed at first glance.
·
The Motley Fool
Prediction: This Will Be Nvidia’s Stock Price in 2027 After Its Phenomenal Q3 Results
Nvidia's latest results indicate that its impressive growth is sustainable.
·
The Motley Fool
If You’d Invested $10,000 in Rocket Lab 5 Years Ago, Here’s How Much You’d Have Today — Even After a 60% Crash
SpaceX is the industry leader, but Rocket Lab is proving that there's room for more than one space company.
·
The Motley Fool
Verizon Pays Out $11.7 Billion a Year in Dividends. Here’s the Free Cash Flow Math Behind Its 6.2%-Yielding Payout.
Verizon is a cash flow machine.
·
The Motley Fool
Micron Stock Just Hit Its Lowest Price Since May. I’d Buy More Now.
With most of this year's output already spoken for, has the memory maker's stock dropped too far?
·
The Motley Fool